TREATMENT OF COMBINED ACNE AND GENITOURINARY INFECTIONS CAUSED BY CHLAMYDIA AND MYCOPLASMAS.

OBJECTIVE: The aim: To substantiate, develop and apply in clinical practice a method for the treatment of combined acne and genitourinary infections caused by chlamydia and mycoplasmas. PATIENTS AND METHODS: Materials and methods: Acne was diagnosed clinically. Chlamydia trachomatis; Mycoplasma genitalium; Mycoplasma hominis; Ureaplasma urealyticum were identified using polymerase chain reaction. 30 patients with combined acne and urogenital chlamydia and/or mycoplasmas received sequential oral antibiotic therapy with josamycin (1500 mg daily) and gatifloxacin (400 mg daily) for 10 days each. Simultaneously with antibiotic therapy, concomitant symptomatic and topical treatment was provided. RESULTS: Results: The elimination of pathogens of urogenital chlamydia and/or mycoplasmas was achieved with 29 out of 30 patients (93.3%). At the same time a complete regression of facial rash inflammatory elements was detected at 18 (60%) treated patients, while with the remaining 12 (40%) the regression was significant. CONCLUSION: Conclusions: Antibiotic therapy was used in the treatment for both acne and urogenital chlamydia and/or mycoplasmas. An original method of complex treatment of combined acne and urogenital chlamydia and/or mycoplasmas was substantiated, developed and successfully applied. The offered method of treatment can be considered as a proof of high effectiveness both for elimination of pathogens from the genitourinary system of patients, and for complete or significant elimination of inflammatory facial rash.

Protozoan genital invasions caused by the representatives of trichomonas and giardia.

OBJECTIVE: The aim was to perform systematic review of genitourinary protozoan invasion and analyze their pathogenicity and the ability to influence the genitourinary infections. PATIENTS AND METHODS: Materials and methods: For systematic review of papers the EMBASE and PubMed databases were searched. We also reviewed our own pilot studies using real-time polymerase chain reaction (PCR) to determine Trichomonas tenax, Pentatrichomonas hominis and Giardia lamblia. CONCLUSION: Conclusions: Trichomonas tenax, Pentatrichomonas hominis, Giardia lamblia can cause genitourinary invasion in addition to Trichomonas vaginalis. Their eradication is obligatory at least for not keeping intact pathogenic microorganisms phagocyted by Trichomonas spp. Defining the protozoan forms is important in preventing of genital infections recurrences and reinfections.

Human Papilloma Virus Vaccination Knowledge, Prevalence, Risk Factors, and HPV Detection in 18-26 and 27-45-year-old Men and Women.

The US Food and Drug Administration approved a supplemental application for HPV 9-valent vaccine for 27-45-year-old women and men. The Advisory Committee on Immunization Practices did not recommend catch-up vaccination of adults aged 27-45 years, but recognized that some adults who were not previously vaccinated may be at risk for new HPV infection and might benefit from vaccination in this age range. We decided to compare HPV vaccination knowledge, prevalence, risk factors, and history of HPV detection in cohorts with ages of 18-26 and 27-45 years. Men and women aged 18-45 years were asked to complete an anonymous internet survey about HPV infection and vaccination. Valid answers were received from 524 respondents. HPV vaccination rates were low (from 0.00 to 5.56%). All women aged 27-45 years bought the vaccine at their own cost and were vaccinated after sexual debut. Knowledge on existence of the HPV vaccine was better in women (P<0.01). The overall number of sexual partners was significantly higher in men and in persons aged 27-45 (P<0.05). Women aged 27-45 reported higher prevalence of unprotected vaginal and anal sex, a higher number of sexual partners, and lower HPV-related cancer awareness. Our study showed that better knowledge on HPV vaccination and HPV-related cancer awareness did not lead to higher HPV vaccination rates. A substantial number of individuals aged 27-45 years may benefit from HPV vaccination, and information on HPV vaccination should be actively disseminated by physicians and mass media.